Several studies have used anakinra (an antagonist of the IL-1R1 receptor) or anti-IL-1β monoclonal antibodies in animal models, both of which have been shown to reduce the occurrence of epilepsy (Vezzani, 2015; Dey et al., 2016). Here, IL1B is linked to epilepsy.